α-氨基羟甲基 唑丙酸（AMPA）受体广泛分布于具有兴奋性的神经突触中，在中枢神经系统中起着重要作用，神经退行性障碍、行动障碍、精神疾病、疼痛等许多疾病都涉及到AMPA受体。日本Eisai公司的在研新药Perampanel（E2007）作为首个具有高度选择性和非竞争性的AMPA型谷氨酸盐受体拮抗剂，用于治疗难治性癫痫的部分发作。基于3个Ⅲ期临床试验具有良好结果，2011年该公司已向美国和欧洲提交了该药物的营销许可申请。

The AMPA receptor is widely present in almost all excitatory neuronal synapses. It is believed to play a role in a large number of central nervous system diseases with different underlying pathophysiology, including neurodegenerative disorders, movement disorders, pain and psychiatric disorders. Eisai that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound Perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of refractory partial seizures in patients with epilepsy.